drugset
drugset / Trial / NCT00101205

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT00101205 ↗

Phase 1 Terminated 40 enrolled National Cancer Institute (NCI)
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of oxaliplatin and etoposide in treating young patients with recurrent or refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may also help etoposide work better by making cancer cells more sensitive to the drug. Giving oxaliplatin together with etoposide may kill more cancer cells.

Timeline

Start
2004-11
Primary completion
2012-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule — Intravenous
Subject Oxaliplatin Small molecule — Intravenous

Indications

B-cell childhood acute lymphoblastic leukemia Burkitt lymphoma Hodgkins lymphoma T-cell childhood acute lymphocytic leukemia T-cell large granular lymphocyte leukemia anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma extranodal nasal NK/T cell lymphoma grade III lymphomatoid granulomatosis hairy cell leukemia hepatosplenic T-cell lymphoma intraocular lymphoma large-cell immunoblastic lymphoma mycosis fungoides and variants peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma small intestine lymphoma